The Board declared a cash dividend for the first quarter of 2019 to be paid on March 15 to shareholders of record at the close of business on February 15.
Friday, January 25, 2019
Aptose Biosciences initiated at Oppenheimer
Aptose Biosciences initiated with an Outperform at Oppenheimer. As previously reported, Oppenheimer analyst Matthew Biegler initiated Aptose Biosciences with an Outperform rating and $6 price target, citing the commercial potential of CG-806 in two major hematology/oncology indications. In a research note to investors, Biegler says he believes CG-806 can selectively disable key signaling pathways that cancer cells need without the “safety baggage” usually associated with multi-kinase inhibitors. Biegler says he would be a buyer of Aptose ahead of CG-806’s expected 1H19 entry into the clinic.
AbbVie reports Q4 revenues from hematologic oncology portfolio $1.13B
Global net revenues from the hematologic oncology portfolio were $1.13B, an increase of 50.2% on a reported basis; global IMBRUVICA net revenues were $1.006B, an increase of 42%; global VENCLEXTA net revenues were $124M. Fourth-quarter global HCV net revenues were $862M.
Novartis stockpiles drugs in UK amid possible no-deal Brexit
Swiss-based drug firm Novartis is stocking up on drugs in the U.K ” before a possible no-deal Brexit, which it warned would be “hugely impactful” for patients.” says the Guardian
AzurRx BioPharma initiated at Roth Capital
AzurRx BioPharma initiated with a Buy at Roth Capital. Roth Capital analyst Jerry Isaacson initiated AzurRx BioPharma with a Buy rating and $10.50 price target. In a research note to investors, Isaacson says he assumes MS1819 to treat EPI in CF patients will be approved for the patient population in 2022, and says his model includes pricing starting at $18,000 per patient per year, in line with currently approved PERTs. MS1819 has numerous potential advantages over currently approved treatments, including reduced pill burden, and the fact that it is not derived from an animal source, he adds.
https://thefly.com/landingPageNews.php?id=2853825
Zimmer Biomet receives FDA 510(k) clearance for ROSA Knee System
Zimmer Biomet announced U.S. FDA 510(k) clearance of the ROSA Knee System for robotically-assisted total knee replacement surgeries. ROSA Knee features 3D pre-operative planning tools and real-time, intraoperative data on soft-tissue and bone anatomy designed to improve bone cut accuracy and range of motion gap analysis to potentially improve flexion and restoration of natural joint movement.
https://thefly.com/landingPageNews.php?id=2853837
Subscribe to:
Posts (Atom)